Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities

JMP Securities analyst Michael King raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $101.00) while maintaining a Market Outperform rating after the company announced positive top-line results for the Phase III APOLLO trial.

"We believe patisiran’s success in APOLLO significantly de-risks the other assets in the company’s pipeline, and we have lowered the discount rates for fitusiran, givosiran, and inclisiran to 25% (from 30%), 15% (from 22.5%) and 15% (from 20%), respectively," King said.

You May Also Be Interested In

• Oracle (ORCL) PT Raised to $250 at UBS Following Q1 Results
• The Lovesac Co. (LOVE) PT Lowered to $18 at DA Davidson as Guidance Lowered
• Jersey Mike's Subs (JMKE) PT Raised to $30 at Tigress Financial Partners